The dialyzer market is expected to grow owing to growing number of end-stage renal disease patients and increasing number of patients suffering from diabetes and hypertension. Factors such as the low preference of patients for kidney transplantation, growth in aging population, technological advancements in products, substantial spending by the government for the treatment of end-stage renal disease, an increase in private investment and venture funding to support the development of new products are further adding to the growth of the market. An increasing number of dialysis centers, growth opportunities in emerging markets, and growing adoption of home dialysis treatment development of new dialysis modalities offer significant growth opportunities for leading players active in the global dialyzer market.
The dialyzer is known as a renal machine that is a critical instrument for supporting the vitality of patients suffering from renal failure. It uses blood to pump arterial blood through the dialyzer, blood tube, and needle and then back to the veins of the patients. The most basic technique of blood purification arises from the use of hemodialyzer. Hence most new blood purification treatment products such as the clinical use on septicemia, high cholesterol treatment and albumin dialysis in liver all rely on the manufacturing technology of hemodialyzer.
However, factors such as low consumer awareness regarding kidney diseases as well as the various treatments, particularly in developing economies are likely to hamper growth. Also, product recalls and decrease in medical reimbursements to dialysis centers would also restrain the growth of the market. Ineffective reimbursement scenario in developing countries and stringent regulatory policies for the approval of new dialysis products are curtailing the growth of this market. Moreover, low cost of kidney transplantation, high procedural cost and high competition among market players are some of the biggest challenges faced by industry players.
The global dialyzer market is segmented broadly into hemodialysis (products & services) and peritoneal dialysis (products & services). The hemodialysis segment accounts for the larger share of the global dialysis market. Among the patients receiving regular dialysis treatment, 89% are treated with hemodialysis while about 11% are treated with peritoneal dialysis. The majority of the patients were treated in dialysis clinics. The hemodialysis market includes consumables, machines, and services. Based on modality, the hemodialysis market is classified into, short daily hemodialysis, nocturnal hemodialysis, and conventional hemodialysis. The hemodialysis market also includes water treatment systems market and its sub-segments, which are portable water disinfection system and central water disinfection system. The peritoneal dialysis market includes peritoneal dialysis services, concentrates/dialysates, machines, catheters, and transfer sets. Moreover, the global dialysis market has also been classified by end users into home dialysis and in-center dialysis. The in-center dialysis market includes independent dialysis centers and hospitals; whereas, the home dialysis market includes home hemodialysis and peritoneal dialysis.
The prevalence rate varies greatly from region to region. In developing countries it can be way below 100. It averages just over 1,100 in the European countries. Prevalence is very high in countries such as the U.S. and Japan, being well over 2,000. The significant difference in prevalence rates is due to genetic pre-disposition and cultural habits, such as nutrition and eating habits, distribution of renal risk factors (such as diabetes and hypertension), differences in age demographics. On the other hand, access to good quality dialysis treatment is still limited in a lot of countries. Patients with terminal kidney failure are not included in the prevalence statistics.
North America holds the largest share of dialyzer market due to structured reimbursement system, the rapid adoption rate of advanced technologies, well-equipped dialysis centers/hospitals, increasing the prevalence of diabetes and hypertension, a high number of dialysis centers, and availability of skilled nephrologists. Asia-Pacific region is expected to grow the fastest during the forecast period due to rising end stage renal disease patient population base, increasing awareness about new dialysis treatment modalities, increasing number of independent dialysis centers, upcoming government initiatives to develop new dialysis facilities, expansion of global players and improving insurance and reimbursement scenario.
Although the demand for dialyzers is increasing annually, new entrants must be equipped with cost & quality advantages to compete with the bigger players. Medical equipment expenses account only for 15% while the renal dialysis services account for the remaining 85%. Some of the key players in the dialyzer industry are ATLANTIC BIOMEDICAL Pvt. Ltd, Angelini Pharma Inc., Chengdu Weilisheng Biotech Co., Ltd., Foshan KangYu of medical equipment Co., LTD, Fuan Enterprise, Guangzhou Widgery Biology Technology Co., Ltd., Health Care Surgical Equipment, Jihua Medical Apparatus And Instruments Co., Ltd., Jilin Saneee Science And Technology Co., Ltd., M S Medicals Pvt. Ltd., Meditop Co., Ltd., Minntech, Novaflux, Sandor Medicaids Pvt. Ltd., Universe Surgical Equipments Co, Zhengzhou Nigale Electronic Technology Co., Ltd.
